| abstract |
This disclosure relates to antibodies having anti-angiogenic activity. More specifically, this disclosure relates to antibodies to ROBO4 and pharmaceutical compositions containing such antibodies. The object of the present disclosure is to provide an anti-angiogenic anti-RBO4 antibody, a pharmaceutical composition containing the anti-RBO4 antibody, a method of inhibiting angiogenesis using the antibody, and the like. It is another object of the present disclosure to provide a method for producing the antibody. The antibodies of this disclosure activate the downstream signal of ROBO4 and have inhibitory activity against cell migration induced by VEGF or bFGF. The antibodies of this disclosure also exhibit anti-angiogenic effects in vivo models. Thus, the problems of the prior art have been solved. |